Affiliate(s):
Japan Tobacco
The XenoMouse technology platform, used to generate ABX-EGF, was originally developed by Xenotech LP, an equally owned limited partnership formed in 1991 by Cell Genesys and JT America, Japan Tobacco's (JT)USA subsidiary. When Cell Genesys created Abgenix in 1996 as a wholly owned subsidiary, Cell Genesys assigned its interest in Xenotech to Abgenix, and in December 1999, Abgenix became sole owner of the XenoMouse technology platform by acquiring all of JT America's interest in Xenotech. Abgenix paid $47 million to JT America for its 50% interest as well as $10 million as compensation to JT to relinquish certain option and license rights to which it was entitled. JT obtained a research license to use XenoMouse technology and options to license the technology for a small number of antigen targets each year. Abgenix will also provide JT with licenses to related technology, obtaining $10 million in return. JT also retains options to, or licenses on, several antigen targets it previously nominated under the Xenotech structure. For all antibody products generated using XenoMouse technology and developed by JT, JT will make license fee payments to Abgenix as well as royalty payments on any product sales. JT and its subsidiaries are estimated to have invested more than $40 million in the creation of the XenoMouse technology; however, JT's emphasis will now be on generating antibody products for its pharmaceutical division to market itself rather than on creating a royalty based income stream.

Lonza Biologics (terminated 6/03)
In June 2003, Abgenix terminated the Agreement with Lonza based on expansion of its own manufacturing capability.

In July 2001, Abgenix and Lonza entered into an agreement giving Abgenix right to enter into exclusive negotiations with Lonza for an additional manufacturing supply agreement for Lonza to make available to Abgenix, for a period of up to 5 years, extendable for an additional 2-year period, approximately 25% of the annual capacity of a cell culture production suite for large scale manufacturing of products that was under construction. The exclusive negotiation period was extended to expire no earlier than June 30, 2002. Financial terms of the agreements were not disclosed.

In November 2000, Abgenix and Lonza Biologics entered into a manufacturing supply agreement for Lonza to make available exclusively to Abgenix, for a period of 5 years, a cell-culture production suite, with associated purification capacity, within Lonza's UK facility. The agreement included an option to extend the initial 5-year term. This dedicated cell culture production suite became available to Abgenix in the third quarter of 2001. Abgenix gained access to production capacity, and scheduling flexibility, Lonza retained responsibility for, and control over, the facility's employees, and its operation.

Takeda Pharmaceutical C
In February 2008, Amgen and Takeda Pharmaceutical Company entered into an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline (one of which is included as an option), including Vectibix (panitumumab). Amgen retains certain co-promotion rights in Japan on all programs.

Current as of: February 12, 2010

Affiliate(s):
Onyx Pharmaceuticals   
Sorafenib is being co-developed by Bayer Pharmaceuticals and Onyx Pharmaceuticals. The co-development collaboration calls for Onyx to fund 50% of the development and marketing costs for sorafenib worldwide, except in Japan. In return, Onyx has a 50/50 profit share in the USA, where the companies plan to co-promote the product if approved. In all other countries (except Japan) Bayer has exclusive marketing rights and Onyx's profit share is less than 50%. In Japan, Bayer will fund product development and Onyx will receive a royalty.

In September 2002, initiation of the phase II clinical program earned Onyx a $5 million loan milestone payment.

In April 1996, the agreement was amended to allow, that during the research term, Onyx and Bayer, to propose additional cancer research targets or programs outside of ras for inclusion, by mutual agreement, in the research collaboration. No additional targets have been proposed by either party during the period ended December 31, 1996. In addition, Bayer agreed that the research collaboration would continue for its full five-year scheduled term (through January 1999), subject only to termination for breach or in the event of the acquisition of Onyx. The agreement provides for Bayer to pay Onyx an aggregate of $25.0 million to fund research efforts over the five-year research term, of which $5.2 million was recorded by the Company as revenue in 1996, $5.2 million in 1995, and $5.5 million in 1994. In addition, Bayer made a $13.5 million equity investment in Onyx in 1994. Under the agreement, compounds that demonstrate the required level of activity in collaboration assays, as established by the Joint R&D Committee (JRDC), are subject to exclusive rights under the collaboration. Bayer will funds all preclinical work necessary to determine which compounds to take into clinical development and to obtain approval for conducting clinical trials. The parties will share equally all costs of developing each product worldwide (excluding Japan), subject to each party's right to elect not to pay such costs. Under the agreement, Bayer shall make substantial payments to Onyx, based on achievement of development milestones, which are subject to repayment by Onyx out of its share of marketing profits and royalties, subject to certain annual limitations.

Bayer shall market the products worldwide (excluding Japan), and Onyx has the option to co-promote such products in the USA, provided that Onyx share equally all costs of development in which case its expenses would be paid out of product sales. Onyx and Bayer will share equally the profits or losses from jointly developed commercialized products. Bayer has the sole and exclusive right to develop and market these compounds as royalty bearing products in Japan, and will bear all related development expenses. Furthermore, Bayer has the sole and exclusive right to develop and market any compounds active against Bayer-proposed targets as royalty bearing products. In addition, either party may independently develop a compound as a royalty bearing product if the JRDC declined such party's proposal to select the compound for joint development.

In February 1994, Onyx entered into a collaboration with Bayer relating to the ras program. Onyx is responsible for conducting research on the ras signaling pathways, identifying leads for drug screening and developing drug discovery assays. Bayer will screen its compound libraries, synthesized analogs of identified leads and conduct preclinical and clinical trials. In addition, Bayer will fund Onyx' research.